Publications directory

Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm

The web Directory of Information Materials for People Affected by Cancer is regularly updated and currently has details of over 1,900 booklets, leaflets, books and audiovisual materials for people affected by cancer. Most have been published in the last five years but we have included some older ones that are still useful.

Results: 96

Cover image of 'DA (Daunarubicin) and ARAc for acute myeloid leukaemia. A guide for patients'

DA (Daunarubicin) and ARAc for acute myeloid leukaemia. A guide for patients (December 2018)

Leukaemia Care

This booklet describes DA treatment, a combination of the drugs daunorubicin and cytarabine (Ara-C), used primarily as induction chemotherapy in patients with newly diagnosed acute myeloid meukaemia. It describes how DA is given, and the possible side-effects. Includes a glossary and details of further support and information.

Cover image of 'Adult acute lymphoblastic leukaemia (ALL). A guide for patients'

Adult acute lymphoblastic leukaemia (ALL). A guide for patients (October 2018)

Leukaemia Care

This booklet explains what acute lymphopblastic leukaemia (ALL) is, and describes the symptoms, diagnosis, and treatment options. It also covers everday life with ALL and how to talk to your haematologist, family and friends. 

Cover image of 'Common side effects of treatment. A guide for patients'

Common side effects of treatment. A guide for patients (October 2018)

Leukaemia Care

Cancer treatment can cause side-effects and sometimes these can be more difficult to manage than the illness itself. Some of these are common and experienced by many, some are much rarer and occur in very few patients. This booklet is designed to provide you with information about the common side-effects you may experience, what to expect and how they may be managed. It covers the following side effects: increased chance of infection; fatigue; hair loss; anaemia; gastrointestinal side-effects (nausea and vomiting, appetitie changes, constipation, diarrhoea); mouth changes; cognitive effects; pain and tingling; fertility; cardiac and lung toxicity; and secondary cancer risk. It also includes a glossary and details of useful contacts and further support.

Cover image of 'Childhood acute myeloid leukaemia (AML). A guide for parents'

Childhood acute myeloid leukaemia (AML). A guide for parents (April 2018)

Leukaemia Care

Being told that your child has acute myeloid leukaemia (AML) can be a shock and very upsetting, particularly when you may never have heard of the disease. This booklet describes childhood AML, what causes it, who it affects, how it affects your child’s body, what symptoms to expect and likely treatments. It also covers everyday life and childhood AML and talking about childhood AML. Includes a glossary of terms and details of useful contacts and further support. 

Cover image of 'Hairy cell leukaemia. A guide for patients'

Hairy cell leukaemia. A guide for patients (April 2018)

Leukaemia Care

Hairy cell leukaemia (HCL) is a blood cancer that affects the lymphocytic (antibody producing) white blood cells produced by the bone marrow. This booklet describes what causes it, who it affects, how it affects your body, the symptoms and diagnosis, and treatment options. It also covers everyday life and HCL and talking about HCL. Includes a glossary of terms and details of useful contacts and further support.

Cover image of 'Essential thrombocythaemia (ET). A guide for patients'

Essential thrombocythaemia (ET). A guide for patients (April 2018)

Leukaemia Care

Essential thrombocythaemia (ET) belongs to a group of conditions called myeloproliferative neoplasms (MPNs), which also includes polycythaemia vera and myelofibrosis. ET is a chronic condition that is characterised by too many platelets (blood cells that helps the blood clot) in the blood. This booklet explains what ET is, what causes it, who it affects, how it affects your body, what symptoms to expect and likely treatments.

Cover image of 'ATRA and anthracycline based therapy for acute myeloid leukaemia (AML). A guide for patients'

ATRA and anthracycline based therapy for acute myeloid leukaemia (AML). A guide for patients (March 2018)

Leukaemia Care

All-trans retinoic acid (ATRA), known as Tretinoin (Vesanoid®) is the acid form of vitamin A, which is used with chemotherapy for induction of remission in patients with confirmed acute promyelocytic leukaemia (APL), a subtype of acute myeloid leukaemia. This booklet describes the use of ATRA along with the chemotherapy drugs idarubicin and mitoxantrone.

Cover image of 'The emotional impact of a blood cancer. A guide for patients'

The emotional impact of a blood cancer. A guide for patients (October 2018)

Leukaemia Care

This booklet describes some of the more challenging emotional responses you may experience as you adjust to life following a diagnosis of blood cancer. It must be noted that this information is mainly written in the context of acute leukaemia and is for those who are receiving intensive treatment. However, anyone with a blood cancer diagnosis may find this information useful.

Cover image of 'Chronic myeloid leukaemia (CML) TKIs and TFR. A guide for patients'

Chronic myeloid leukaemia (CML) TKIs and TFR. A guide for patients (September 2018)

Leukaemia Care

This booklet is written for patients with Philadelphiachromosome-positive (Ph+) CML. It explains what tyrokinase inhibitors are and how they work. It covers imatinib, nilotinib, dasatinib, bosutinib, ponatinib, including how they are given and possible side-effects.

Cover image of 'Future treatments in acute myeloid leukaemia (AML). A guide for patients'

Future treatments in acute myeloid leukaemia (AML). A guide for patients (October 2018)

Leukaemia Care

The main treatment for acute myeloid leukaemia (AML) is chemotherapy, including targeted therapy. This might be followed by a stem cell transplant, and surgery and radiotherapy may be used in special circumstances. New therapies are being developed and investigated and this booklet describes several of these: clofarabine (DNA synthesis inhibitor); gilteritinib and quizartinib (tyrosine kinase inhibitors); venetoclax (B-cell lymphoma-2 (BCL2) inhibitor); and Vyxeos® (a combination of daunorubicin and cytarabine. 

Sorry, no publications found.
Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm